Page last updated: 2024-08-23

razoxane and Neoplasms

razoxane has been researched along with Neoplasms in 80 studies

Research

Studies (80)

Timeframe	Studies, this research(%)	All Research%
pre-1990	32 (40.00)	18.7374
1990's	22 (27.50)	18.2507
2000's	18 (22.50)	29.6817
2010's	7 (8.75)	24.3611
2020's	1 (1.25)	2.80

Authors

Authors	Studies
Armenian, SH; de Baat, EC; Feijen, EAM; Kremer, LCM; Mavinkurve-Groothuis, AMC; Mulder, RL; van Dalen, EC	1
Cohen, GI; Emami, B; Gradishar, WJ; Green, DM; Hagerty, KL; Hensley, ML; Kewalramani, T; Meropol, NJ; Mitchell, RB; Schuchter, LM; Thigpen, JT; Trotti, A; von Hoff, D; Wasserman, TH	1
Jones, RL	1
Ahn, HS; Choi, HS; Choi, JY; Kang, HJ; Noh, CI; Park, ES; Shin, HY; Yun, YS	1
Dervisis, NG; FitzPatrick, WM; Kitchell, BE	1
Caron, HN; Kremer, LC; Raphaël, MF; van Dalen, EC; van den Berg, H	1
Caron, HN; Dickinson, HO; Kremer, LC; van Dalen, EC	1
De Grève, J; Fontaine, C; Noens, L; Pierre, P	1
Franco, VI; Harake, D; Henkel, JM; Lipshultz, SE; Miller, TL	1
Kang, M; Kim, KI; Oh, JM; Shin, WG; Song, YC	1
Gisterek, I; Mazur, G; Wróbel, T; Włodarska, I; Zymliński, R; Łacko, A	1
Hellmann, K	5
Komagata, H; Sakai, H	1
Al-Khadimi, Z; Chow, WA; Doroshow, JH; Frankel, P; Lawrence, J; Leong, L; Lim, D; Longmate, J; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Synold, TW; Tetef, ML; Twardowski, P; Yen, Y	1
Champion, C; Durand, JB; Ewer, MS; Gibbs, H; Lenihan, DJ; Swafford, J; Tong, AT; Yeh, ET; Yusuf, SW; Zafarmand, AA	1
Gershanovich, ML	1
Anderson, B	1
Cvetković, RS; Scott, LJ	1
Blazek, B; Elbl, L; Hrstkova, H; Michalek, J; Tomaskova, I	1
Kik, K; Szmigiero, L	1
Alvarez, JA; Barry, E; Lipshultz, SE; Miller, TL; Scully, RE	1
Hasinoff, BB; Herman, EH	1
Hogle, WP	1
Pawlicki, M; Zuchowska-Vogelgesang, B	1
Liu, TF; Zhang, XF; Zhang, ZY	2
Belt, R; Haas, C; Hoogstraten, B; Liesmann, J	1
Bruno, S; Macdonald, JS; Penta, JS; Poster, DS	1
Campbell, ED; Carter, WH; Stablein, DM; Wampler, GL	1
Davis, HL; Earhart, RH; Koeller, JM; Robins, HI; Rodriguez, R; Tormey, DC; Tutsch, KD; Vogel, CL	1
Bruno, S; Macdonald, JS; Marsoni, S; Penta, J; Poster, DS	1
Giraldi, T; Sava, G	1
Bamberg, M; Holfeld, H	1
Baker, D; Constable, W; Elkon, D; Rinehart, L	1
Hochster, H; Speyer, J; Wasserheit, C	1
Armand, JP; de Forni, M	1
Lewis, C	1
Hale, JP; Lewis, IJ	1
Bu'Lock, FA; Gabriel, HM; Martin, RP; Mott, MG; Oakhill, A	1
Basser, RL; Cebon, J; Duggan, G; Green, MD; Mihaly, G; Rosenthal, MA; Sobol, MM	1
Catimel, G; Clavel, M; Merrouche, Y	1
Furue, H	1
Lipshultz, SE	1
Trotti, A	1
Mott, MG	1
Spencer, CM; Wiseman, LR	1
Brion, N; Paule, B	1
Bramwell, V; Moran, LA; Seymour, L	1
Broder, G; Cohen, GI; Gradishar, WJ; Green, DM; Hensley, ML; Langdon, RJ; Lindley, C; Meropol, NJ; Mitchell, RB; Negrin, R; Pfister, DG; Schuchter, LM; Szatrowski, TP; Thigpen, JT; Von Hoff, D; Wasserman, TH; Winer, EP	1
Chow, W; Doroshow, JH; Gandara, D; Groshen, S; Johnson, K; Lenz, HJ; Leong, L; Margolin, K; Morgan, R; Raschko, J; Shibata, S; Somlo, G; Synold, TW; Tetef, ML; Yen, Y	1
Field, EO; Hellmann, K	1
Hensley, ML; Meropol, NJ; Schuchter, LM; Winer, EP	1
Alford, DA; Allen, LM; Creaven, PJ	1
Carter, SK; Slavik, M	2
Hellmann, K; Hill, BT	1
Hagemann, G; Töllner, D	1
Cavalli, F	1
Boggust, WA; McGauley, H	1
Carter, WH; Crews, SL; Howells, R; Wampler, GL	1
Cangir, A; Dyment, PG; Komp, DM; Land, VJ; Sexauer, CL; Starling, KA	1
Catalano, RB; Engstrom, PF; Paul, AR	1
Bakowski, MT	1
Duke, DI	1
Carlson, RW	1
Blum, RH; Downey, A; Goldenberg, A; Oratz, R; Speyer, JL; Walsh, C	1
Kamen, B; Krischer, JP; Vats, T	1
Hellmann, K; Rhomberg, W	1
Dorr, RT	1
Hammershaimb, LD; Hurson, SB; Marsoni, S; Simon, RM; Ungerleider, RS	1
Earhart, RH; Glaubiger, DL; Gribble, TJ; Holcenberg, JS; Kamen, BA; Pratt, CB; Tutsch, KD; Ungerleider, RS	1
Agarwal, RP; Davila, E; Eisenberger, M; Gorowski, E; Kosinski, J; Savaraj, N; Vogel, CL	1
Wideröe, R	1

Reviews

32 review(s) available for razoxane and Neoplasms

Article	Year
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert review of cardiovascular therapy, 2008, Volume: 6, Issue:10 Topics: Aged; Animals; Anthracyclines; Antibiotics, Antineoplastic; Bone Marrow; Cardiotonic Agents; Chelating Agents; Child; Clinical Trials as Topic; Drug Evaluation, Preclinical; Heart Diseases; Humans; Neoplasms; Razoxane	2008
Cardioprotective interventions for cancer patients receiving anthracyclines. The Cochrane database of systematic reviews, 2011, Jun-15, Issue:6 Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cytoprotection; Heart Diseases; Humans; Neoplasms; Randomized Controlled Trials as Topic; Razoxane	2011
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future cardiology, 2012, Volume: 8, Issue:4 Topics: Adiponectin; Age Factors; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; Antibiotics, Antineoplastic; Antioxidants; Carbazoles; Cardiolipins; Cardiotonic Agents; Carvedilol; Doxorubicin; Erythropoietin; Heart; Heart Diseases; Humans; Lipid Peroxidation; Liposomes; Neoplasms; Piperazines; Propanolamines; Purines; Razoxane; Risk Factors; Sildenafil Citrate; Sulfones; Survivors; Ventricular Dysfunction, Left	2012
[Cardiac toxicity in cancer therapy]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2002, Volume: 13, Issue:73 Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cardiomyopathy, Dilated; Cardiovascular Agents; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Neoplasms; Radiotherapy, Adjuvant; Razoxane; Risk Factors; Sarcoma	2002
Dynamics of tumour angiogenesis: effect of razoxane-induced growth rate slowdown. Clinical & experimental metastasis, 2003, Volume: 20, Issue:2 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Razoxane	2003
[Chemotherapy-induced cardiac toxicity and management]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:6 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Echocardiography; Heart; Heart Diseases; Humans; Monitoring, Physiologic; Neoplasms; Razoxane	2003
Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation, 2004, Jun-29, Volume: 109, Issue:25 Topics: Anthracyclines; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biomarkers; Biopsy; Cardiovascular Diseases; Cytokines; Heart; Humans; Neoplasms; Pericardium; Radiation Injuries; Radiotherapy; Razoxane; Risk Factors	2004
Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients. Pediatric blood & cancer, 2005, Jun-15, Volume: 44, Issue:7 Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Humans; Neoplasms; Razoxane	2005
Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy. Drugs, 2005, Volume: 65, Issue:7 Topics: Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Cardiovascular Diseases; Humans; Neoplasms; Randomized Controlled Trials as Topic; Razoxane	2005
[Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs]. Postepy higieny i medycyny doswiadczalnej (Online), 2006, Volume: 60 Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Chelating Agents; Neoplasms; Razoxane	2006
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:8 Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiovascular Agents; Drug Interactions; Drug Monitoring; Heart; Heart Diseases; Humans; Neoplasms; Razoxane; Risk Factors	2007
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovascular toxicology, 2007, Volume: 7, Issue:2 Topics: Animals; Antineoplastic Agents; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Enzyme Inhibitors; Heart Diseases; Humans; Neoplasms; Prodrugs; Razoxane; Topoisomerase II Inhibitors	2007
Cytoprotective agents used in the treatment of patients with cancer. Seminars in oncology nursing, 2007, Volume: 23, Issue:3 Topics: Amifostine; Antineoplastic Agents; Cytoprotection; Fibroblast Growth Factors; Glutamine; Humans; Mesna; Neoplasms; Razoxane	2007
[New antineoplastic agents, their value and use]. Przeglad lekarski, 1982, Volume: 39, Issue:8 Topics: Aminacrine; Antineoplastic Agents; Aspartic Acid; Cisplatin; Etoposide; Humans; Ifosfamide; Interferons; Medroxyprogesterone; Medroxyprogesterone Acetate; Methyltestosterone; Neoplasms; Phosphonoacetic Acid; Razoxane; Tamoxifen; Teniposide; Vinca Alkaloids	1982
ICRF-187 in clinical oncology. Cancer clinical trials, 1981, Volume: 4, Issue:2 Topics: Animals; Antineoplastic Agents; Dogs; Drug Evaluation; Drug Therapy, Combination; Humans; Leukemia L1210; Mice; Neoplasms; Neoplasms, Experimental; Piperazines; Razoxane	1981
Selective antimetastatic drugs (review). Anticancer research, 1981, Volume: 1, Issue:3 Topics: Animals; Antineoplastic Agents; Hemostasis; Humans; Leukemia; Leukemia, Experimental; Mice; Neoplasm Metastasis; Neoplasms; Neoplasms, Experimental; Protease Inhibitors; Rats; Razoxane	1981
Cardiotoxicity and cardioprotection during chemotherapy. Current opinion in oncology, 1995, Volume: 7, Issue:4 Topics: Adult; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Heart; Heart Diseases; Humans; Interleukin-2; Male; Neoplasms; Paclitaxel; Razoxane; Retrospective Studies; Survivors	1995
Cardiotoxicity of chemotherapy. Current opinion in oncology, 1994, Volume: 6, Issue:4 Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Fluorouracil; Heart Diseases; Humans; Mice; Mitoxantrone; Neoplasms; Paclitaxel; Prospective Studies; Rabbits; Rats; Razoxane	1994
A review of the use of chemoprotectants in cancer chemotherapy. Drug safety, 1994, Volume: 11, Issue:3 Topics: Adrenocorticotropic Hormone; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; Humans; Mesna; Neoplasms; Peptide Fragments; Razoxane	1994
Anthracyclines: cardiotoxicity and its prevention. Archives of disease in childhood, 1994, Volume: 71, Issue:5 Topics: Antibiotics, Antineoplastic; Child; Child, Preschool; Drug Administration Schedule; Heart; Humans; Neoplasms; Razoxane; Risk Factors	1994
Hematopoietic growth factors and chemoprotectants: should we move toward a two-step process for phase I clinical trials in oncology? Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:6 Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Heart Diseases; Hematopoietic Cell Growth Factors; Humans; Kidney Diseases; Neoplasms; Neutropenia; Razoxane	1993
[Topoisomerase inhibitors developing in Japan]. Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzopyrans; Camptothecin; Diketopiperazines; Glycosides; Humans; Irinotecan; Neoplasms; Phenazines; Piperazines; Razoxane; Topotecan	1993
Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1996, Volume: 4, Issue:4 Topics: Adult; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Male; Neoplasms; Razoxane; Treatment Outcome	1996
Toxicity antagonists in cancer therapy. Current opinion in oncology, 1997, Volume: 9, Issue:6 Topics: Amifostine; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Growth Substances; Humans; Mesna; Neoplasms; Palliative Care; Radiotherapy; Razoxane; Superoxide Dismutase	1997
Anthracycline cardiotoxicity and its prevention. Annals of the New York Academy of Sciences, 1997, Sep-17, Volume: 824 Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Child; Child, Preschool; Doxorubicin; Heart; Humans; Infant; Neoplasms; Razoxane	1997
Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs, 1998, Volume: 56, Issue:3 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Chelating Agents; Heart Diseases; Humans; Neoplasms; Razoxane	1998
[Anticancer chemotherapy. Prevention of complications]. Presse medicale (Paris, France : 1983), 1998, Dec-12, Volume: 27, Issue:39 Topics: Antidotes; Antineoplastic Agents; Dose-Response Relationship, Drug; Glutathione; Heart; Humans; Iron Chelating Agents; Mesna; Neoplasms; Protective Agents; Razoxane; Vomiting	1998
Investigational drugs under study by the United States National Cancer Institute. Cancer treatment reviews, 1976, Volume: 3, Issue:1 Topics: Acrylates; Alkylating Agents; Ancitabine; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Chemical Phenomena; Chemistry; Chromomycins; Cisplatin; DNA, Neoplasm; Drug Evaluation, Preclinical; Etoposide; Humans; Ifosfamide; Leukemia L1210; Mice; Mitosis; National Institutes of Health (U.S.); Neoplasms; Neoplasms, Experimental; Razoxane; Tegafur; Teniposide; United States	1976
Current investigational drugs of interest in the Chemotherapy Program of the National Cancer Institute. National Cancer Institute monograph, 1977, Issue:45 Topics: Altretamine; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Cisplatin; Dacarbazine; Doxorubicin; Drug Evaluation; Female; Guanazole; Humans; Ifosfamide; Male; National Institutes of Health (U.S.); Neoplasms; Nitrogen Mustard Compounds; Nitrosourea Compounds; Razoxane; United States	1977
[New substances in oncologic therapy]. Schweizerische medizinische Wochenschrift, 1978, Aug-12, Volume: 108, Issue:32 Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Cisplatin; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Evaluation, Preclinical; Etoposide; Humans; Neoplasms; Nitrosourea Compounds; Razoxane; Tamoxifen; Vinca Alkaloids; Zinostatin	1978
Radiotherapeutic enhancement by razoxane. Cancer treatment reviews, 1991, Volume: 18, Issue:4 Topics: Animals; Combined Modality Therapy; Female; Humans; Male; Mice; Neoplasm Metastasis; Neoplasms; Radiation-Sensitizing Agents; Razoxane	1991
Chemoprotectants for cancer chemotherapy. Seminars in oncology, 1991, Volume: 18, Issue:1 Suppl 2 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Fluorouracil; Humans; Ifosfamide; Leucovorin; Mesna; Methotrexate; Neoplasms; Razoxane; Sulfhydryl Compounds; Uridine	1991

Trials

12 trial(s) available for razoxane and Neoplasms

Article	Year
Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors. Journal of Korean medical science, 2010, Volume: 25, Issue:9 Topics: Adolescent; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Cohort Studies; Disease-Free Survival; Doxorubicin; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Infant; Male; Neoplasms; Razoxane; Ventricular Function, Left	2010
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies. Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:3 Topics: Adult; Antibiotics, Antineoplastic; Cardiovascular Agents; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Neoplasms; Neutropenia; Ofloxacin; Razoxane; Sarcoma; Sepsis; Treatment Outcome	2004
Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients. European journal of pediatrics, 2005, Volume: 164, Issue:11 Topics: Adolescent; Anthracyclines; Antineoplastic Agents; Blood Pressure; Body Mass Index; Cardiovascular Agents; Child; Child, Preschool; Czech Republic; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Echocardiography, Stress; Female; Follow-Up Studies; Heart; Heart Rate; Humans; Infant; Male; Neoplasms; Prospective Studies; Razoxane; Time Factors; Treatment Outcome	2005
Preliminary report on AT1727 as a potential radiosensitizer. International journal of radiation oncology, biology, physics, 1984, Volume: 10, Issue:12 Topics: Clinical Trials as Topic; Combined Modality Therapy; Humans; Lung Neoplasms; Neoplasms; Piperazines; Radiation-Sensitizing Agents; Random Allocation; Razoxane; Sarcoma; Soft Tissue Neoplasms	1984
Bis-diketopiperazine derivatives in clinical oncology: ICRF-159. Cancer clinical trials, 1980, Volume: 3, Issue:4 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Evaluation; Drug Interactions; Head and Neck Neoplasms; Humans; Lymphoma; Mice; Neoplasm Metastasis; Neoplasms; Piperazines; Razoxane	1980
Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. British heart journal, 1993, Volume: 70, Issue:2 Topics: Adolescent; Antibiotics, Antineoplastic; Child; Child, Preschool; Heart; Heart Diseases; Humans; Neoplasms; Pilot Projects; Razoxane	1993
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:8 Topics: Adult; Aged; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasms; Razoxane; Stomatitis; Vomiting	1994
Anthracycline cardiotoxicity and its prevention. Annals of the New York Academy of Sciences, 1997, Sep-17, Volume: 824 Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Child; Child, Preschool; Doxorubicin; Heart; Humans; Infant; Neoplasms; Razoxane	1997
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:6 Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cations; Chromatography, High Pressure Liquid; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasms; Razoxane; Time Factors	2001
Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor. Journal of cancer research and clinical oncology, 1992, Volume: 118, Issue:1 Topics: Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Neoplasms; Razoxane	1992
Phase II trial of ICRF-187 in children with solid tumors and acute leukemia. Investigational new drugs, 1991, Volume: 9, Issue:4 Topics: Acute Disease; Adolescent; Child; Drug Evaluation; Humans; Leukemia; Neoplasms; Razoxane	1991
ADR-529 (ICRF-187). Cancer investigation, 1989, Volume: 7, Issue:1 Topics: Clinical Trials as Topic; Humans; Neoplasms; Piperazines; Razoxane	1989

Other Studies

37 other study(ies) available for razoxane and Neoplasms

Article	Year
Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane. Pediatric blood & cancer, 2023, Volume: 70, Issue:10 Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Child; Dexrazoxane; Humans; Neoplasms; Polyketides; Razoxane	2023
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-01, Volume: 27, Issue:1 Topics: Amifostine; Antineoplastic Agents; Fibroblast Growth Factor 7; Humans; Mesna; Neoplasms; Practice Guidelines as Topic; Radiation-Protective Agents; Razoxane	2009
Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient. Veterinary and comparative oncology, 2010, Volume: 8, Issue:4 Topics: Animals; Cardiovascular Agents; Dog Diseases; Dogs; Doxorubicin; Drug Therapy, Combination; Gastrointestinal Diseases; Heart Diseases; Neoplasms; Razoxane	2010
Should anthracyclines and dexrazoxane be used for children with cancer? The Lancet. Oncology, 2011, Volume: 12, Issue:1 Topics: Anthracyclines; Antineoplastic Agents; Child; Heart; Humans; Neoplasms; Neoplasms, Second Primary; Razoxane	2011
Savene® (dexrazoxane) use in clinical practice. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:5 Topics: Anthracyclines; Antibiotics, Antineoplastic; Belgium; Catheterization, Central Venous; Chelating Agents; Data Collection; Debridement; Extravasation of Diagnostic and Therapeutic Materials; Humans; Neoplasms; Razoxane; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome	2012
Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients. Journal of chemotherapy (Florence, Italy), 2012, Volume: 24, Issue:5 Topics: Adolescent; Age Factors; Anthracyclines; Cardiovascular Agents; Cardiovascular Diseases; Child; Child, Preschool; Female; Heart Function Tests; Hospitals, Teaching; Humans; Infant; Male; Neoplasms; Razoxane; Republic of Korea; Retrospective Studies	2012
[Cardioxan: prevention of anthracycline-related cardiotoxicity]. Voprosy onkologii, 2004, Volume: 50, Issue:4 Topics: Adolescent; Adult; Age Factors; Aged; Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cardiotonic Agents; Cardiovascular Agents; Chelating Agents; Child; Clinical Trials as Topic; Doxorubicin; Echocardiography; Electrocardiography; Female; Heart; Heart Diseases; Humans; Immunosuppressive Agents; Leukemia, Experimental; Male; Mice; Mice, Inbred C57BL; Neoplasms; Neoplasms, Experimental; Razoxane; Time Factors	2004
Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-10, Volume: 25, Issue:29 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Hodgkin Disease; Humans; Neoplasms; Razoxane; Research Design; Risk; Risk Factors	2007
Phase II evaluation of AT-1727 in advanced human cancer. Chinese medical journal, 1983, Volume: 96, Issue:8 Topics: Antineoplastic Agents; Drug Evaluation; Humans; Neoplasms; Piperazines; Razoxane	1983
Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy. Cancer, 1981, Apr-15, Volume: 47, Issue:8 Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Granulocytes; Humans; Infusions, Parenteral; Leukocyte Count; Leukopenia; Myeloproliferative Disorders; Neoplasms; Piperazines; Platelet Count; Razoxane	1981
Drug activity and therapeutic synergism in cancer treatment. Cancer research, 1982, Volume: 42, Issue:8 Topics: Animals; Antineoplastic Agents; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Melanoma; Mice; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Experimental; Rats; Razoxane; Teniposide	1982
Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patients. Cancer research, 1982, Volume: 42, Issue:12 Topics: Blood Proteins; Chromatography, High Pressure Liquid; Humans; Infusions, Parenteral; Kinetics; Neoplasms; Piperazines; Razoxane; Stereoisomerism	1982
[General principles and new trends of cytostatic tumor therapy]. Strahlentherapie, 1980, Volume: 156, Issue:5 Topics: Antineoplastic Agents; Cisplatin; Dacarbazine; Doxorubicin; Drug Therapy, Combination; Humans; Immunotherapy; Neoplasms; Nitrosourea Compounds; Podophyllotoxin; Radiation-Sensitizing Agents; Razoxane	1980
The influence of ICRF-159 and levamisole on the incidence of metastases following local irradiation of a solid tumor. Cancer, 1981, Nov-15, Volume: 48, Issue:10 Topics: Animals; Female; Levamisole; Mice; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Radiation-Induced; Piperazines; Radiotherapy; Radiotherapy Dosage; Razoxane; Risk	1981
Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:2 Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Child; Heart; Heart Diseases; Humans; Neoplasms; Razoxane	1996
Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:2 Topics: Adult; Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Child; Heart; Heart Diseases; Humans; Neoplasms; Razoxane	1996
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC, 1999, Volume: 3, Issue:2 Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Epirubicin; Evidence-Based Medicine; Female; Heart; Heart Failure; Humans; Neoplasms; Odds Ratio; Randomized Controlled Trials as Topic; Razoxane; Time Factors; Treatment Outcome	1999
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:10 Topics: Adult; Amifostine; Antineoplastic Agents; Cardiovascular Agents; Humans; Mesna; Neoplasms; Protective Agents; Radiation-Protective Agents; Radiotherapy; Razoxane	1999
Effect of ICRF159 on the mammalian cell cycle: significance for its use in cancer chemotherapy. Journal of the National Cancer Institute, 1970, Volume: 44, Issue:3 Topics: Animals; Antineoplastic Agents; Cell Death; Drug Screening Assays, Antitumor; Mammals; Neoplasms; Razoxane; Time Factors; Tumor Cells, Cultured	1970
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12 Topics: Amifostine; Antineoplastic Agents; Chelating Agents; Humans; Mesna; Neoplasms; Protective Agents; Radiation-Protective Agents; Radiotherapy; Razoxane	2002
The bioavailability in man of ICRF-159 a new oral antineoplastic agent. The Journal of pharmacy and pharmacology, 1975, Volume: 27, Issue:12 Topics: Administration, Oral; Adult; Aged; Biological Availability; Drug Administration Schedule; Feces; Humans; Middle Aged; Neoplasms; Piperazines; Razoxane; Time Factors	1975
Razoxane and methotrexate resistance. Lancet (London, England), 1977, Jan-01, Volume: 1, Issue:8001 Topics: Cell Line; Cell Survival; Drug Resistance; Humans; Lymphocytes; Methotrexate; Neoplasms; Piperazines; Razoxane	1977
[The effect of bleomycin, ICRF 159 and of simultaneous X-ray application on CHO-fibroblasts]. Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology, 1977, Volume: 88, Issue:3 Topics: Animals; Bleomycin; Cell Survival; Drug Therapy, Combination; Neoplasms; Piperazines; Razoxane	1977
Inhibition of collagen peptidase in HeLa cells and human tumours by compounds including drugs used in cancer therapy. British journal of cancer, 1978, Volume: 38, Issue:2 Topics: Antineoplastic Agents; Aprotinin; Collagen; Cyclophosphamide; Edetic Acid; Fluorouracil; HeLa Cells; Humans; Microbial Collagenase; Neoplasms; Phenanthrolines; Razoxane; Thiotepa	1978
On determining the levels of treatment to optimize the probability of a favorable response. Cancer treatment reports, 1977, Volume: 61, Issue:5 Topics: Altretamine; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Leukemia L1210; Mice; Mice, Inbred Strains; Models, Biological; Neoplasms; Razoxane; Statistics as Topic	1977
ICRF-159 (razoxane) in the treatment of pediatric solid tumors: a Southwest Oncology Group study. Cancer treatment reports, 1979, Volume: 63, Issue:8 Topics: Adolescent; Child; Drug Administration Schedule; Drug Evaluation; Hematopoiesis; Humans; Neoplasms; Piperazines; Razoxane	1979
Razoxane - a new anti-tumour agent. Drug and therapeutics bulletin, 1978, Jan-20, Volume: 16, Issue:2 Topics: Humans; Neoplasms; Piperazines; Razoxane	1978
Radiosensitizers. Antibiotics and chemotherapy, 1978, Volume: 23 Topics: Animals; Cell Survival; Humans; In Vitro Techniques; Mice; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Razoxane	1978
Phase I trial of ICRF-159 in combination with 1.3 bis-(2-chloroethyl)-1-nitrosourea (MeCCNU). Cancer clinical trials, 1978,Summer, Volume: 1, Issue:2 Topics: Bone Marrow; Drug Evaluation; Drug Therapy, Combination; Gastrointestinal Neoplasms; Humans; Neoplasms; Piperazines; Razoxane; Semustine	1978
ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane. Cancer treatment reviews, 1976, Volume: 3, Issue:2 Topics: Animals; Antineoplastic Agents; Cricetinae; Dogs; Drug Synergism; Haplorhini; Humans; Immunosuppressive Agents; Leukemia; Neoplasm Metastasis; Neoplasms; Piperazines; Rabbits; Radiation-Sensitizing Agents; Rats; Razoxane; Teratogens	1976
Prenatal effects of the cancer chemotherapeutic drug ICRF 159 in mice, rats, and rabbits. Teratology, 1975, Volume: 11, Issue:1 Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antineoplastic Agents; Female; Fetus; Gestational Age; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Neoplasms; Piperazines; Pregnancy; Rabbits; Rats; Razoxane	1975
Reducing the cardiotoxicity of the anthracyclines. Oncology (Williston Park, N.Y.), 1992, Volume: 6, Issue:6 Topics: Antibiotics, Antineoplastic; Biopsy, Needle; Endocardium; Heart Diseases; Heart Failure; Heart Function Tests; Humans; Myocardium; Neoplasms; Razoxane; Risk Factors; Sensitivity and Specificity	1992
Tolerance to antineoplastic agents in children and adults. Cancer treatment reports, 1985, Volume: 69, Issue:11 Topics: Adult; Ancitabine; Antineoplastic Agents; Child; Dose-Response Relationship, Drug; Drug Evaluation; Drug Tolerance; Humans; Hypotension; Leukemia; Lymphoma; Neoplasms; Posture; Razoxane; Retrospective Studies	1985
ICRF-187 and razoxane in cancer treatment. Lancet (London, England), 1987, Sep-26, Volume: 2, Issue:8561 Topics: Female; Humans; Neoplasms; Piperazines; Razoxane	1987
Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer treatment reports, 1986, Volume: 70, Issue:6 Topics: Adolescent; Adult; Blood Coagulation Tests; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Drug Administration Schedule; Drug Evaluation; Enzymes; Half-Life; Hematologic Diseases; Humans; Kinetics; Neoplasms; Piperazines; Razoxane; Stereoisomerism; Tissue Distribution	1986
Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors. Investigational new drugs, 1987, Volume: 5, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Piperazines; Razoxane	1987
Optimization of cancer radiotherapy with selective sensitizers. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1987, Volume: 163, Issue:6 Topics: Cells, Cultured; Chemical Phenomena; Chemistry; Combined Modality Therapy; Humans; Metronidazole; Misonidazole; Neoplasms; Oxygen Consumption; Radiation Dosage; Radiation-Sensitizing Agents; Razoxane	1987